![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Oncol. , 22 October 2024
Sec. Pediatric Oncology
Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1487777
This article is a correction to:
Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations
A Corrigendum on
Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations
By Bashiri FA, Hundallah K, Abukhaled M, Alyahya MM, Al Futaisi A, Alshowaeir D, Al Tawari A, Abdullah S, Maaz AUR, AlShamsi ET, Alshuaibi W, Alotaibi F and Aldhalaan H (2024) Front. Oncol. 14:1323176. doi: 10.3389/fonc.2024.1323176
In the published article, there was an error in the FDA approval status of mirdametinib.
A correction has been made to section 6.4 Treatment of NF1, subsection 6.4.4 Targeted therapies, paragraph 1. This sentence previously stated:
“Mirdametinib is a recently approved MEK inhibitor in July 2023 for the management of NF1-associated plexiform neurofibromas (105).”
The corrected sentence appears below:
“Other MEK inhibitors, mirdametinib, binimetinib, and trametinib are being investigated for the treatment of NF1-associated plexiform neurofibromas (104, 105).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: children, Gulf Cooperation Council, management, neurofibromatosis type 1, referral
Citation: Bashiri FA, Hundallah K, Abukhaled M, Alyahya MM, Al Futaisi A, Alshowaeir D, Al Tawari A, Abdullah S, Maaz AUR, AlShamsi ET, Alshuaibi W, Alotaibi F and Aldhalaan H (2024) Corrigendum: Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations. Front. Oncol. 14:1487777. doi: 10.3389/fonc.2024.1487777
Received: 28 August 2024; Accepted: 27 September 2024;
Published: 22 October 2024.
Edited and Reviewed by:
Tang-Her Jaing, Chang Gung Children’s Hospital, TaiwanCopyright © 2024 Bashiri, Hundallah, Abukhaled, Alyahya, Al Futaisi, Alshowaeir, Al Tawari, Abdullah, Maaz, AlShamsi, Alshuaibi, Alotaibi and Aldhalaan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Fahad A. Bashiri, ZmJhc2hpcmlAa3N1LmVkdS5zYQ==
†ORCID: Fahad A. Bashiri, orcid.org/0000-0003-1436-6727
Khaled Hundallah, orcid.org/0000-0003-2570-8462
Musaad Abukhaled, orcid.org/0009-0003-3539-1144
Mossaed Mohammed Alyahya, orcid.org/0000-0003-0938-6192
Amna Al Futaisi, orcid.org/0000-0002-8035-0849
Daniah Alshowaeir, orcid.org/0000-0001-5144-4056
Asmaa Al Tawari, orcid.org/0000-0003-1706-8848
Shaker Abdullah, orcid.org/0009-0001-3955-1032
Ata Ur Rehman Maaz, orcid.org/0000-0003-1399-5994
Eman Taryam AlShamsi, orcid.org/0000-0002-5580-8723
Walaa Alshuaibi, orcid.org/0000-0002-5571-8971
Faisal Alotaibi, orcid.org/0000-0002-5871-2209
Hesham Aldhalaan, orcid.org/0000-0001-7288-8588
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.